1001080-50-7

1001080-50-7 structure

Name: Sotatercept
Chemical Name: Sotatercept
CAS Number: 1001080-50-7
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-05-01 22:56:08
Modify Date: 2025-08-21 14:03:59
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions[1][2][3][4][5].

Name	Sotatercept

Description	Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions[1][2][3][4][5].
Related Catalog	Research Areas >> Cancer Research Areas >> Inflammation/Immunology
Target	ACVR2A
In Vitro	Sotatercept (100 μg/mL) 下调了基质细胞分泌的 VEGF、抑瘤素 M (OSM)、IL-6、BMP-2、MMP-1 和 MMP13 表达水平[5]。
References	[1]. Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215. [2]. Raje N, et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010 Oct;12(5):586-97. [3]. Abdulkadyrov KM, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165(6):814-23. [4]. Sherman ML, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013 Nov;53(11):1121-30. [5]. Iancu-Rubin C, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013 Feb;41(2):155-166.e17.

No Any Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1289114-53-9	1803787-15-6
1803758-73-7	1804500-28-4
1270069-99-2	1806346-04-2
1388074-49-4	1806345-17-4
1806345-19-6	1422434-67-0